New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q2 2017 call → NOWe need answer YES/NO. Need determine if management indicates economic terms of newest business have stepped up meaningfully above company's own recent norm, and improvement only begun to flow into reported results because most business still old terms. We need parse transcript. Question asks about "economic terms of company's newest business — prices, rates, fees, spreads, contract sizes, durations, or profitability at which its most recent deals, orders, contracts, renewals, or transactions are being struck" have stepped up above own recent norm, and only begun to flow into reported results. We need look for management statements about new business terms improving vs own recent past, and that reported results still old terms. This is a specific phenomenon. In earnings calls, often about pricing power, rate increases, etc. Here Biogen is pharma. Need see if any mention of new contracts, pricing, deals, etc. They discuss MS value-based contracts, SPINRAZA launch, biosimilars, business development deals. But question specifically "economic terms of company's newest business" - maybe about licensing deals? They acquired BIIB092, BIIB093. Did they indicate terms improved? No. Maybe about SPINRAZA pricing? They mention revenue, uptake, but not terms improving vs norm. They mention TECFIDERA revenue growth, gross to net improved. But not "new business terms" step up. Need answer NO unless clear. Let's examine transcript for any mention of "pricing" or "terms" or "contracts". They discuss value-based contracting in MS: "aligning price to patient outcomes" and "adjusting price for patients initiating therapy who discontinue." But not that terms improved vs own norm. They say "pilot" and "provide valuable information." Not economic step-up. They discuss biosimilars: "BENEPALI market leader" etc. No pricing terms. They discuss SPINRAZA: revenue $203M, U.S. $195M, inventory build, coverage. No mention of price increases or better terms. They discuss aducanumab, pipeline. No. Question asks "newest business" maybe "business development" deals? They acquired Remedy, licensed BMS. Did they say terms? No. Thus answer NO. Need only YES/NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...